As a reminder, this conference is being recorded. At this time, I would like to hand the call over to your moderator, Eric Ribner of Investor Relations. Thank you. You may begin. Good afternoon, everyone, and welcome to Eyenovia's Q2 2023 Earnings Call, Earnings Conference Call and Audio Webcast. With me today are Eyenovia's Chief Executive Officer, Michael Rowe; Chief Financial Officer, John Gandolfo; and Chief Operating Officer, Bren Kern. This afternoon, we issued a press release announcing financial results for the three and six-month period ending June 30, 2023. We encourage everyone to read today's press release, as well as Eyenovia's quarterly report on Form 10-Q for the quarter ended June 30, 2023, which will be filed with the SEC tomorrow, August 11, and our most recent filed 10-K. The company's press release and annual report are also available on our website at www.eyenovia.com. In addition, this conference call is being webcast to the company's website and will be archived for future reference. Please note that on today's call, we will be discussing products, product concepts, and candidates, some of which have yet to receive FDA approval. Please also note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during the call, Eyenovia's management will be making forward-looking statements. Actual results could differ materially from those stated or implied by those forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are subject to a number of risks, which are described in more detail in our annual report in Form 10-K and other SEC filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 10, 2023. Eyenovia undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities law. With that said, I'd like to turn the call over to Michael Rowe, Eyenovia's Chief Executive Officer. Michael? Thank you, Eric, and welcome everyone to our Q2 2023 Financial Results Conference Call. We had an extremely productive Q2, and I am excited to share with you our progress this afternoon. During our last conference call, we spoke of our efforts to begin our targeted launch of Mydcombi and our goal of partnering with other companies to leverage and monetize the Optejet technology beyond our own development programs. Today, we will provide an update for both of these topics, starting with Mydcombi and our recent first commercial sale. As you'll recall, in May, we received FDA approval of Mydcombi, the first and only fixed combination of tropicamide and phenylephrine, and the only ophthalmic spray for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. We are proud to have delivered the first FDA-approved product that leverages our Optejet dispensing device. This important advancement was featured at the annual Ophthalmology Technology Forum in June, where we highlighted the innovative nature of Mydcombi and the future of the Optejet technology to the ophthalmic community, including potential industry partners, thought leaders, and investors. We're thrilled to have initiated sales of Mydcombi to a targeted group of professional offices. Ophthalmologists, optometrists, technicians, and patients are now experiencing the benefits of Mydcombi themselves, and together we are learning how the product can streamline practices and help with patient management. As we announced last week, upon receipt of our New York pharmacy license, we achieved our first commercial sale of Mydcombi. The world-renowned board-certified ophthalmologist, Dr. Nathan Radcliffe, who becomes first to incorporate Mydcombi into his daily practice. Last week, we conducted training at OC Retina in Orange, California, and as soon as our California pharmacy license is received, we anticipate initiating sales in this state. We're already receiving positive feedback from doctors, technicians, and patients, and we anticipate this will only increase with additional sales and marketing wrap-up. To that end, we are in the process of formally adding additional commercial manufacturing sites to support Mydcombi, including our Redwood City facility, as well as Coastline International as a secondary site. Bren will provide additional details during his manufacturing overview. These additional sites will provide us with increased capacity to meet and anticipate demand, not only of Mydcombi, but potential future ophthalmic therapies utilizing the Optejet. If you'd like to find out more about Mydcombi, track our launch progress, and hear what doctors and patients are saying about the product, you can go to the website at Mydcombi.com. Now, I'd like to talk a bit more about our efforts to leverage and monetize the Optejet technology through partnerships with other companies. We have engaged in active discussions in this area with no fewer than four companies across a variety of topical ophthalmic markets. Some of these discussions take longer than would be assumed because we need to first determine if the products under discussion are compatible with the Optejet. This is something that is true for any container closure system, and usually, those tests include both spray performance as well as material compatibility. We anticipate being able to announce the first of these arrangements very shortly. Our goal with all of these discussions is to marry our leading delivery technology with a new or unique drug asset to bring the best of both worlds to patients and prescribers while providing near-term revenue and/or capital opportunities for the company. I'll now provide an update on Apersure, our intended brand name for the MicroLine project. Apersure is our proprietary topical on-demand pilocarpine-based therapeutic candidate that we are developing for the temporary improvement in near vision associated with presbyopia. As you may know, presbyopia is the age-related hardening of the eye's lens causing blurred near vision. This addressable market represents over 18 million people in the United States alone between the ages of 40 and 55, who otherwise never wore glasses and have the resources for a cash pay product. Our proprietary market research suggests this could be nearly a billion-dollar annual market in the U.S. alone. As we discussed last quarter, we received feedback from the FDA outlining a clear path forward for this program towards a New Drug Application or NDA. We continue to make progress on this front. Apersure is being designed for use with our more advanced Gen-2 Optejet device, which has been optimized for in-home use. These will be manufactured in our Redwood City facility, and we anticipate that manufacturing of registration batches will commence in Q4 of this year. Based on the FDA requirement of 12 months of real-time stability data on the final packaged product before filing an NDA, we plan to file the NDA approximately 12 months after we run those batches, so late 2024. Apersure differs from the current topical drug treatment option for presbyopia on the market and those in development, in that it is a drug device combination. As such, many optometrists would be able to include Apersure as an offering to patients along with eyeglasses. Apersure has been described by some in market research as a second pair of invisible glasses, or the way to gain functional vision for those times when wearing glasses is not desirable. We tested this concept with 100 optometrists, who found that Apersure would meet the needs of both themselves and their patients better than any other pharmaceutical option that they have or believe will have available. These doctors estimated that Apersure ophthalmic spray could capture as much as one-third of the presbyopia pharmaceutical market, with the other five products, all eye drops, competing for the remaining two-thirds of that market. If approved, we believe that Apersure, administered using the Optejet, will stand out as the one and only spray, distinguished by its ergonomic design, ease of use, and potentially advantageous side effect profile. At this point, I'd like to turn the call over to our Chief Operating Officer, Bren Kern, for our manufacturing update. Bren? Thank you, Michael. As Michael mentioned, we continue to expeditiously build out our manufacturing capabilities in support of Mydcombi and registration batches for Apersure. To expand upon the Mydcombi targeted launch, we have filed with the FDA a request to approve the use of an additional manufacturing site, Coastline International. The FDA has given us a PDUFA date of mid-November 2023 for this site to be approved for use. Coastline has already been manufacturing clinical supply for us for over a year and has extensive experience with the Optejet. Following the PDUFA, we anticipate this to be a smooth ramp-up, and the team at Coastline is eager to support our commercial manufacturing needs. We also submitted our Redwood City facility to the FDA as an additional manufacturing site and anticipate hearing from the FDA soon with that PDUFA date. Our Redwood City facility has made significant progress in qualifying our Gen 2 fill and finish line. The team is scheduled to begin media fills this month, a monumental step in qualifying this production equipment to support Apersure and the remainder of the Eyenovia drug product lines. As Michael mentioned, we are targeting the initiation of Apersure registration batches in the fourth quarter of 2023. Our Reno facility continues to make significant progress in establishing base and injector manufacturing. On our last earnings call, we noted that the facility construction had been completed and the staff has taken occupancy. Since then, production equipment has been received, installation of the equipment is currently underway, and qualification activities are in the final planning stages. I continue to be excited about the progress we've made to enhance our manufacturing. With an increased manufacturing capacity, we'll be better positioned to meet the anticipated growth demand of Optejet, particularly with the approval and commercial availability of Mydcombi. I would now like to turn the call over to our Chief Financial Officer, John Gandolfo, to provide a financial update. John? Thanks, Brent. For Q2 of 2023, net loss was approximately $6.2 million, or 0.16 per share, compared to a net loss of approximately $7.2 million, or 0.22 per share for Q2 of 2022. Research and development expenses totaled approximately $2.8 for Q2 of 2023, as compared to 3.6 million for Q2 of 2022. For Q2 of 2023, G&A expenses were approximately $3.1 compared to 3.5 million for Q2 of 2022. Total operating expenses for Q2 of 2023 were approximately $6 compared to 7.1 million for Q2 of 2022. As of June 30, 2023, company's cash and cash equivalents were approximately $17.5 compared to 22.9 million as of December 31, 2022. This includes an additional $5 million drawdown on our credit line with Avenue Capital that was triggered by the FDA approval of Mydcombi. For a brief update on our licensing revenues, in addition to the cash balance noted above, we have a receivable from our licensed partners of approximately $430,000 as of June 30, 2023, and expect a reimbursement payment of approximately $2 million from Arctic Vision for product development expenses in the second half of 2023. I'll now provide an update on our existing licensing programs with Bausch Health for MicroPine in the US and Canada, and Arctic Vision for all three of our products in China and South Korea. Bausch + Lomb is continuing to enroll in the ongoing Phase 3 CHAPERONE trial of MicroPine, a proprietary atropine formulation for the reduction of pediatric myopia progression. It has been shown in clinical studies to slow myopia progression by 60% or more. There are currently no FDA-approved drug therapies for this indication, and if left untreated, this can result in retinal detachment, myopic retinopathy, as well as vision loss. Our agreement with Arctic Vision covers Greater China and South Korea and covers MicroPine, MicroLine, and Mydcombi, and provides us sales royalties in addition to development milestones. MicroPine, in particular, is a significant opportunity in China for pediatric myopia. If approved, MicroPine could be a significant source of non-dilutive funding for our company over the long term. To date, our license agreements have generated approximately $16 million in license fees, with the potential to earn an additional $60 million in net license and development milestones, as well as reimbursable expenses over the next four years. Upon commercialization, if our products are approved, Eyenovia is also eligible to earn significant sales royalties. We are also continuing to assess potential pipeline expansion opportunities similar to our Formosa agreement, and we will continue to leverage the Optejet technology to address unmet needs in additional large ophthalmic indications. Finally, Eyenovia was added to the Small Cap Russell 2000 and Broad Market Russell 3000 indices, effective in June, as part of the annual Russell Indexes reconstitution. The reconstitution captures the 4,000 largest U.S. stocks as of April 28, 2023, ranked by total market capitalization. In conclusion, we are very pleased with our performance through the first half of 2023. To summarize some of the key highlights, we received FDA approval of Mydcombi and initiated sales to select professional offices. Registration batches for our Apersure presbyopia program are expected to initiate in the fourth quarter of 2023. We continue to advance discussions with multiple potential partners to leverage the Optejet in additional ophthalmic indications. We're continuing to build out our manufacturing capabilities with Coastline manufacturing in our Redwood City facilities, anticipated to come to support Mydcombi production in late 2023 and early 2024, respectively. Our licensing agreements with Arctic Vision and Bausch + Lomb are progressing well and remain a promising avenue for significant development and regulatory milestones, as well as the potential for sales royalties. That concludes our prepared remarks today. We would now like to open the call to questions. Operator? Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for your questions. Our first questions come from the line of Matthew Caufield with H.C. Wainwright. Please proceed with your question. Yeah. Hey, guys. Can you hear me okay? Yes, Matt. Yes. Great. Michael and team, thanks for taking our questions and congrats, obviously, on the ongoing Optejet progress this quarter. So first of two questions. Regarding development of the Gen-2 device, particularly for on-demand presbyopia, is there a point in the future where all devices will be Gen-2, both prospectively for MicroLine or Apersure, as well as for Mydcombi? Just kind of wondering if there's any sort of manufacturing streamlining, you know, if all Optejets are based on the Gen-2 design. Thank you, Matt, for that question. The answer is ultimately yes. The reason we're going from Gen-1 to Gen-2 is not just because Gen two, ergonomically and aesthetically, we believe is, is a nicer product, but it's has far fewer parts than the Gen-1 does. While the system that you use to spray is identical, the parts within the Gen-2 make it a lot easier and simpler and less costly to actually build. In the long term, we do want to get everything onto that platform. Got it. Very helpful. Just one kind of follow-up on, on the presbyopia progress. Have the, the Generation two studies for microbial challenge, human factor, electronic safety, and any drug stability data, have those all been completed, or are any of those efforts kind of still ongoing presently? Some of those are completed, some are ongoing, but they will all be done. ... probably by the end of this year. They're not a rate-limiting step, and there's nothing in there that causes us any pause because a lot of this is very similar to what we did with the Gen- 1. The rate-limiting step is the 12-month stability. Mm-hmm. Got it. Very helpful. All right. Thank you very much, guys, and congrats again on the progress this quarter. Thank you, Matt. Thank you. Our next questions come from the line of Matthew Kaplan with Ladenburg Thalmann. Please proceed with your questions. Hi, this is Raymond in for Matt. Thanks for taking our question, and congrats on all the progress. I'm glad to see Mydcombi being used. I guess relating to that, I was wondering, how should we think about kind of the stages of the launches, as it progresses in terms of licenses, uptake, and so forth? Thanks. A follow-up thing. John, do you want to take this, or I can? It's up to you. No, it's okay. I, I think that with respect to Mydcombi, we're focusing initially, as Michael mentioned, on a, a targeted launch program. We feel that with the Coastline manufacturing coming up towards the end of this year, we'll be able to give better visibility to the investor community as to guidance of Mydcombi once we have that in place. We expect probably with that third quarter earnings call, which will be in November, we'll be able to give guidance for, you know, obviously, 2024, probably beyond as well. With respect to licenses or partnership opportunities, they remain a key focus of ours. Michael highlighted that, that we're speaking to no less than four parties at this time. That continues to be a major focus for the company. Okay. Yes, no, definitely appreciate that color. I guess I was wondering, are there any early feedback you're getting, and are you do you see how you would like to incorporate that and as you are getting ready for a national launch next year? Yes. It's funny that you ask this question because we just were speaking with some of the technicians at one of the offices in New York. They've now used the product for a week, what they're finding out is they started by using it on a few patients. They told us today they used it on every patient. 40 patients they dilated today. The more they use it, the more they like it. What they're also finding is that the duration of dilation is less than it is with eye drops, which is actually a positive. One of the reasons people don't like to get dilated is they end up being dilated for hours and hours and hours through the rest of the day. It's looking like, with Mydcombi, you get the efficacy, that you need, and then it, it may very well not last as long, which is a positive you get back to normal. We're definitely looking into that some more. Oh, appreciate that detail. Very helpful. I'll jump back in the queue. Thanks. Thank you. Thank you. I'm showing no further questions at this time. I'd like to hand the floor back to management for any closing comments. Thank you. Thanks, everybody, for joining us today. That concludes today's call. We are very pleased with the year we have had so far. We've had our first FDA approval and commercial sale of Mydcombi. Our Apersure presbyopia program is progressing, and our manufacturing capabilities are continuing to grow. We look forward to continued momentum through the rest of 2023 and beyond. Thank you again for joining us. We look forward to Q3 update. Thank you. This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.